The degree to which someone trusts the information depicted in a chart can depend on their assumptions about who made the ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Preclinical data on PN-881, a first-in-class oral peptide targeting the IL-17 pathway and fully owned by Protagonist, are also being presented at EADV. 3 The Company expects that the first subject ...

BioRender, the world's leading AI-powered platform for scientific communication, has announced a strategic partnership with Anthropic to integrate its extensive library of vetted, scientifically ...